Also tempering of the inflammation, e.g. by blockade of IL-1 or TNF-α may theoretically be effective in controlling acute GVHD [46], but pre-emptive use of IL-1 antagonist in a prospective randomized clinical trial did not show an advantage over placebo [47] and probably needs further adjustments. The gene discussed is TNF; the disease is acute graft versus host disease.